Prudential Financial Inc. Has $10.56 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Prudential Financial Inc. lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.0% during the 2nd quarter, HoldingsChannel reports. The firm owned 115,727 shares of the medical equipment provider’s stock after acquiring an additional 8,609 shares during the period. Prudential Financial Inc.’s holdings in Zimmer Biomet were worth $10,555,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Zimmer Biomet by 0.9% in the second quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock valued at $2,120,751,000 after buying an additional 198,370 shares in the last quarter. Dodge & Cox increased its holdings in shares of Zimmer Biomet by 2.3% during the first quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock worth $2,214,305,000 after buying an additional 446,018 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Zimmer Biomet by 8.7% in the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock valued at $520,752,000 after acquiring an additional 458,903 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Zimmer Biomet by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock valued at $465,480,000 after acquiring an additional 69,485 shares during the last quarter. Finally, Primecap Management Co. CA boosted its holdings in shares of Zimmer Biomet by 0.6% during the 2nd quarter. Primecap Management Co. CA now owns 4,710,830 shares of the medical equipment provider’s stock valued at $429,675,000 after acquiring an additional 27,860 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $97.66 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $85.33 and a fifty-two week high of $114.44. The company has a 50 day simple moving average of $96.89 and a two-hundred day simple moving average of $96.81. The company has a market capitalization of $19.35 billion, a PE ratio of 23.76, a P/E/G ratio of 2.29 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter in the previous year, the company earned $1.74 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ZBH shares. UBS Group dropped their target price on Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating for the company in a research report on Thursday, November 6th. Canaccord Genuity Group lowered their price objective on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research note on Monday, November 10th. Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Sunday, November 16th. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $109.00.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.